[1] Ferris RL et al. (2016) Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. New Engl J Med 375: 1856–1867
[2] Cohen EEW et al. (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open- label, phase 3 study. Lancet 393: 156–167
[3] Burtness B et al. (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394: 1915–1928
[4] Taylor MH et al. (2020) Phase Ib/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 38: 1154–1163
[5] Massarelli E et al. (2019) Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients with Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol 5: 67–73
